Comparative Pharmacology
Head-to-head clinical analysis: AZASITE versus ERYTHROMYCIN LACTOBIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZASITE versus ERYTHROMYCIN LACTOBIONATE.
AZASITE vs ERYTHROMYCIN LACTOBIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Erythromycin lactobionate inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing the translocation of peptides. It may also act as a motilin receptor agonist, enhancing gastrointestinal motility.
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
1-4 g/day IV divided every 6 hours; maximum 4 g/day. Infuse over 20-60 minutes.
None Documented
None Documented
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
Terminal elimination half-life: 1.4-2.0 hours in adults with normal renal function. In patients with anuria, half-life may be prolonged up to 4.8-6.0 hours.
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
Primarily biliary excretion (80-90% as unchanged drug and metabolites); renal excretion accounts for 10-15% of the dose. Fecal elimination is minimal (<5%).
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic